PIA
SPRO icon

Piedmont Investment Advisors’s Spero Therapeutics SPRO Stock Holding History

Piedmont Investment Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-116
Closed -$2K – 2101
2018
Q2 		$2K Buy
+116
New +$1.48K ﹤0.01% 2633

Other funds holding SPRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Piedmont Investment Advisors's SPRO Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Spero Therapeutics (SPRO) in Q3 2018, closing a stake of 116 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in SPRO in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 53 funds tracked by Wall St. Rank hold SPRO as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Spero Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 116 Spero Therapeutics shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Spero Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Spero Therapeutics position peaked at $2K in Q2 2018.
  • 53 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.